Hemab raises USD 135m in Series B financing
In 2025, the hemophilia company wants to have started five clinical programs – and investors have now provided a solid foundation to get there.
by albert rønning-andersson, translated by daniel pedersen
Backed by a huge investment, biotech company Hemab is now one step closer to its ambition of becoming a world-leading developer of new medicines for neglected bleeding disorders, which are to this day still being treated as in the 1950s with simple blood transfusions.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Holdings invests in newly merged blood disease company
For subscribers
